Ipsen S.A.

Ipsen S.A.

IPSEY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$14.87B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ipsen S.A.Ipsen S.A.26.80.96%20%20.2
$47.84

Current Fair Value

6.1% upside

Undervalued by 6.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$14.87 Billion
Enterprise Value$13.86 Billion
Annual dividend$0.46
Dividend yield0.96%
Earnings per Share$1.28
Beta0.32
Outstanding Shares329,743,000

Return

Return on Equity20.38%ROE
Return on Assets12.87%
Return on Invested Capital31.12%

Valuation & Multiples

P/E Ratio26.84P/E Ratio
PEG129.73PEG
Price to Sales1.96Price to Sales
Price to Book Ratio3.22Price to Book Ratio
Enterprise Value to Revenue1.75
Enterprise Value to EBIT7.78
Enterprise Value to Net Income14
Total Debt to Enterprise0.07
Debt to Equity0.2Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
July 30, 2026
EPS
$2.11
Est. $1.86
Revenue
$2.52 B
Est. $2.42 B

Next Earnings Call

Expected Date
February 11, 2027
EPS Estimate
$2.32
Consensus analyst estimate
Revenue Estimate
$2.69 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Ipsen S.A.

5,535 employees
CEO: David G. Loew

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and ac...